N-of-1 trials: The epitome of personalized medicine?
| Autor: | Samuel JP; Department of Pediatrics, Center for Clinical Research and Evidence-Based Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA., Wootton SH; Department of Pediatrics, Center for Clinical Research and Evidence-Based Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA., Tyson JE; Department of Pediatrics, Center for Clinical Research and Evidence-Based Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of clinical and translational science [J Clin Transl Sci] 2023 Jul 03; Vol. 7 (1), pp. e161. Date of Electronic Publication: 2023 Jul 03 (Print Publication: 2023). |
| DOI: | 10.1017/cts.2023.583 |
| Abstrakt: | Observational studies are notoriously susceptible to bias, and parallel-group randomized trials are important to identify the best overall treatment for eligible patients. Yet, such trials can be expected to be a misleading indicator of the best treatment for some subgroups or individual patients. In selected circumstances, patients can be treated in n-of-1 trials to address the inherent heterogeneity of treatment response in clinical populations. Such trials help to accomplish the ultimate goal of all biomedical research, to optimize the care of individual patients. Competing Interests: The authors have no conflicts of interest to declare. (© The Author(s) 2023.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|